SCHEMBL3282602

SCHEMBL3282602

CC(=O)N1CCN(c2ccc(Nc3nc(Nc4ccc5cn[nH]c5c4)c4c(C)cn(S(=O)(=O)c5ccc(C)cc5)c4n3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.58
PDGFRB P09619 10/20 0.49
PDGFRA P16234 10/20 0.49
FLT3 P36888 2/20 0.47
EGFR P00533 2/20 0.46
FGFR1 P11362 2/20 0.46
ALK Q9UM73 3/20 0.44
WEE1 P30291 2/20 0.42
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
CCND2 P30279 1/20 0.41
CCND3 P30281 1/20 0.41
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40
ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3280387 0.88 SYK (0.58) SYKPDGFRBPDGFRAFLT3EGFR
SCHEMBL3278828 0.80 SYK (0.67) SYKPDGFRBPDGFRAEGFRFGFR1
SCHEMBL3279013 0.80 KMT2A (0.44) PDGFRBPDGFRA
SCHEMBL3286379 0.79 EGFR (0.57) SYKPDGFRBPDGFRAFLT3EGFR
SCHEMBL3285976 0.78 PDGFRB (0.50) SYKPDGFRBPDGFRAFLT3EGFR
SCHEMBL3279674 0.77 FLT3 (0.48) SYKFLT3EGFRALKCDK4
SCHEMBL3282662 0.76 FLT3 (0.49) SYKFLT3ALKJAK2
SCHEMBL3280106 0.76 SYK (0.65) SYKPDGFRBPDGFRAFLT3EGFR
SCHEMBL3286821 0.75 SYK (0.69) SYKPDGFRBPDGFRAEGFRFGFR1
SCHEMBL13387229 0.74 FLT3 (0.49) SYKFLT3EGFRALKCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK SYK 1/4885PDGFRB 388/4885PDGFRA 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.